Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion

Molecular Psychiatry

Volumn 18, Issue 5, 2013, Pages 557-567

  Ma, T M ^a   Abazyan, S ^b   Abazyan, B ^b   Nomura, J ^b,c   Yang, C ^b   Seshadri, S ^d   Sawa, A ^a,d   Snyder, S H ^a,e   Pletnikov, M V ^a,b,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Neurobiology   (United States)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Department of Psychiatry and Behavioral Sciences   (United States)

^e Johns Hopkins University School of Medicine ^*  (United States)

Author keywords

astrocytes; D serine; DISC1; MK 801; schizophrenia; serine racemase

Indexed keywords

DEXTRO SERINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DIZOCILPINE; MESSENGER RNA; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RACEMASE; AMPHETAMINE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYCLOHEXIMIDE; CYSTEINE PROTEINASE INHIBITOR; DISC1 PROTEIN, HUMAN; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOMERASE; LEUPEPTIN; NERVE PROTEIN; NEUROPROTECTIVE AGENT; PROTEIN BINDING; SERINE; SERINE RACEMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; MOUSE; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD BEHAVIOR; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SCHIZOPHRENIA; STARTLE REFLEX; UBIQUITINATION; ANALYSIS OF VARIANCE; ANIMAL; AUDITORY STIMULATION; BRAIN; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETIC TRANSFECTION; GENETICS; INHIBITION (PSYCHOLOGY); MAZE TEST; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSFORMED CELL LINE; TRANSGENIC MOUSE;

ACOUSTIC STIMULATION; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; BRAIN; CELL LINE, TRANSFORMED; CYCLOHEXIMIDE; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INHIBITION (PSYCHOLOGY); LEUPEPTINS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; RACEMASES AND EPIMERASES; REFLEX, STARTLE; SCHIZOPHRENIA; SERINE; TRANSFECTION;

EID: 84876674591     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.97     Document Type: Article

References (75)

1. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
3. Mothet JP, Parent AT, Wolosker H, Brady Jr RO, Linden DJ, Ferris CD et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 2000; 97: 4926-4931.
4. Shleper M, Kartvelishvily E, Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. 2005; 25: 9413-9417.
5. Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA et al. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 2006; 125: 775-784.
6. Gustafson EC, Stevens ER, Wolosker H, Miller RF. Endogenous D-serine contributes to NMDA-receptor-mediated light-evoked responses in the vertebrate retina. J Neurophysiol 2007; 98: 122-130.
7. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 2009; 14: 719-727.
8. Mori H, Inoue R. Serine racemase knockout mice. Chemistry & Biodiversity 2010; 7: 1573-1578.
9. DeVito LM, Balu DT, Kanter BR, Lykken C, Basu AC, Coyle JT et al. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes, Brain, Behav 2011; 10: 210-222.
10. Sullivan SJ, Esguerra M, Wickham RJ, Romero GE, Coyle JT, Miller RF. Serine racemase deletion abolishes light-evoked NMDA receptor currents in retinal ganglion cells. J Physiol 2011; 589(Pt 24): 5997-6006.
11. Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A 1999; 96: 13409-13414.
12. De Miranda J, Santoro A, Engelender S, Wolosker H. Human serine racemase: moleular cloning, genomic organization and functional analysis. Gene 2000; 256: 183-188.
13. Puyal J, Martineau M, Mothet JP, Nicolas MT, Raymond J. Changes in D-serine levels and localization during postnatal development of the rat vestibular nuclei. J Comp Neurol 2006; 497: 610-621.
14. Williams SM, Diaz CM, Macnab LT, Sullivan RK, Pow DV. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 2006; 53: 401-411.
15. Schell MJ, Brady Jr RO, Molliver ME, Snyder SH. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. 1997; 17: 1604-1615.
16. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-576.
17. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005; 57: 1493-1503.
18. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41-51.
19. Morita Y, Ujike H, Tanaka Y, Otani K, Kishimoto M, Morio A et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry 2007; 61: 1200-1203.
20. Boks MP, Rietkerk T, van de Beek MH, Sommer IE, de Koning TJ, Kahn RS. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. 2007; 17: 567-572.
21. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-585.
22. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
23. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-130.
24. Labrie V, Wong AH, Roder JC. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 2012; 62: 1484-1503.
25. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. Mol Med (Cambridge, Mass) 2003; 9: 3-9.
26. Hamilton SP. Schizophrenia candidate genes: are we really coming up blank? Am J Psychiatry 2008; 165: 420-423.
27. St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990; 336: 13-16.
28. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9: 1415-1423.
29. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 2011; 12: 707-722.
30. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, Ozeki Y et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005; 7: 1167-1178.
31. Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. 2008; 28: 10893-10904.
32. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S et al. Dominantnegative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A 2007; 104: 14501-14506.
33. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007; 54: 387-402.
34. Li W, Zhou Y, Jentsch JD, Brown RA, Tian X, Ehninger D et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A 2007; 104: 18280-18285.
35. Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 2009; 32: 485-495.
36. Ramsey AJ, Milenkovic M, Oliveira AF, Escobedo-Lozoya Y, Seshadri S, Salahpour A et al. Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A 2011; 108: 5795-5800.
37. Seshadri S, Kamiya A, Yokota Y, Prikulis I, Kano S, Hayashi-Takagi A et al. Dis-rupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci U S A 2010; 107: 5622-5627.
38. Kuroda K, Yamada S, Tanaka M, Iizuka M, Yano H, Mori D et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum Mol Genet 2011; 20: 4666-4683.
39. Eastwood SL, Walker M, Hyde TM, Kleinman JE, Harrison PJ. The DISC1 Ser704Cys substitution affects centrosomal localization of its binding partner PCM1 in glia in human brain. Hum Mol Genet 2010; 19: 2487-2496.
40. Sawa A, Pletnikov MV, Kamiya A. Neuron-glia interactions clarify genetic-environmental links in mental illness. Trends Neurosci 2004; 27: 294-297.
41. Henn FA, Henn SW. The psychopharmacology of astroglial cells. Prog Neurobiol 1980; 15: 1-17.
42. Stevens B. Neuron-astrocyte signaling in the development and plasticity of neural circuits. Neuro-Signals 2008; 16: 278-288.
43. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563-569.
44. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Therap 2002; 303: 1-10.
45. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008; 13: 173-186, 115.
46. Lin TN, Wang Q, Simonyi A, Chen JJ, Cheung WM, He YY et al. Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem 2004; 90: 637-645.
47. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, Krasnova IN et al. Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neuro-behavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 2011; 16: 293-306.
48. Kang BN, Ahmad AS, Saleem S, Patterson RL, Hester L, Dore S et al. Death-associated protein kinase-mediated cell death modulated by interaction with DANGER. 2010; 30: 93-98.
49. Miya K, Inoue R, Takata Y, Abe M, Natsume R, Sakimura K et al. Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 2008; 510: 641-654.
50. Mustafa AK, Kumar M, Selvakumar B, Ho GP, Ehmsen JT, Barrow RK et al. Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-serine formation. Proc Natl Acad Sci U S A 2007; 104: 2950-2955.
51. Hashimoto A, Nishikawa T, Oka T, Takahashi K, Hayashi T. Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. J Chromatogr 1992; 582: 41-48.
52. Balan L, Foltyn VN, Zehl M, Dumin E, Dikopoltsev E, Knoh D et al. Feedback inactivation of D-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membrane. Proc Natl Acad Sci U S A 2009; 106: 7589-7594.
53. Pletnikov MV, Xu Y, Ovanesov MV, Kamiya A, Sawa A, Ross CA. PC12 cell model of inducible expression of mutant DISC1: new evidence for a dominant-negative mechanism of abnormal neuronal differentiation. Neurosci Res 2007; 58: 234-244.
54. Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H. Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J Biol Chem 2006; 281: 14151-14162.
55. Porteous DJ, Millar JK, Brandon NJ, Sawa A. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 2011; 17: 699-706.
56. Austin CP, Ma L, Ky B, Morris JA, Shughrue PJ. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport 2003; 14: 951-954.
57. Schurov IL, Handford EJ, Brandon NJ, Whiting PJ. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 2004; 9: 1100-1110.
58. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. 2008; 28: 264-278.
59. Fujii K, Maeda K, Hikida T, Mustafa AK, Balkissoon R, Xia J et al. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol Psychiatry 2006; 11: 150-157.
60. Dumin E, Bendikov I, Foltyn VN, Misumi Y, Ikehara Y, Kartvelishvily E et al. Modulation of D-serine levels via ubiquitin-dependent proteasomal degradation of serine racemase. J Biol Chem 2006; 281: 20291-20302.
61. Deutsch SI, Rosse RB, Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin Neuropharmacol 1997; 20: 375-384.
62. Nilsson M, Carlsson A, Carlsson ML. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 1997; 104: 1195-1205.
63. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T et al. Glycine and D:-serine, but not D:-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology 2008; 198: 363-374.
64. Hashimoto A, Chiba S. Effect of systemic administration of D-serine on the levels of D-and L-serine in several brain areas and periphery of rat. Eur J Pharmacol 2004; 495: 153-158.
65. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010; 90: 285-326.
66. Rosenberg D, Kartvelishvily E, Shleper M, Klinker CM, Bowser MT, Wolosker H. Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration. FASEB J 2010; 24: 2951-2961.
67. Jeon GS, Choi DH, Lee HN, Kim DW, Chung CK, Cho SS. Expression of L-serine biosynthetic enzyme 3-phosphoglycerate dehydrogenase (Phgdh) and neutral amino acid transporter ASCT1 following an excitotoxic lesion in the mouse hippocampus. Neurochem Res 2009; 34: 827-834.
68. Wolosker H. Serine racemase and the serine shuttle between neurons and astrocytes. Biochim biophys acta 2011; 1814: 1558-1566.
69. Yang JH, Wada A, Yoshida K, Miyoshi Y, Sayano T, Esaki K et al. Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-D-aspartate receptor co-agonist, in adult brain. J Biol Chem 2010; 285: 41380-41390.
70. Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. Nature 2010; 463: 232-236.
71. Hikida T, Mustafa AK, Maeda K, Fujii K, Barrow RK, Saleh M et al. Modulation of D-serine levels in brains of mice lacking PICK1. Biol Psychiatry 2008; 63: 997-1000.
72. Kim PM, Aizawa H, Kim PS, Huang AS, Wickramasinghe SR, Kashani AH et al. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci U S A 2005; 102: 2105-2110.
73. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574.
74. Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry 2009; 17: 214-225.
75. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169: 215-233.